Details for Patent: 7,741,358
Summary for Patent: 7,741,358
| Title: | Crystal form of asenapine maleate | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The invention relates to an orthorhombic crystal form of compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7]oxepino[4,5-c]pyrrole (Z)-2-butenedioate, to methods for the preparation of this crystal form and to pharmaceutical compositions comprising an orthorhombic crystal form. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Gerhardus Johannes Heeres | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Forest Laboratories Holdings ULC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US11/399,204 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,741,358 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 7,741,358: Asenapine Maleate Polymorph Scope, Claims, Expiration and Generic RiskUS Patent 7,741,358 protects the orthorhombic crystalline form of asenapine maleate, the active pharmaceutical ingredient used in Saphris sublingual tablets and related asenapine products. The patent does not broadly claim asenapine, asenapine maleate in every physical form, or every dosage form. Its central limitation is a specific solid-state form containing at least about 90 wt.% of the orthorhombic polymorph. The patent includes five protection layers:
The practical commercial issue is whether a generic manufacturer must use the orthorhombic form to produce an FDA-equivalent asenapine product. Because the marketed product is based on asenapine maleate and the patent claims the form used in the commercial drug, the patent has been a key Orange Book and Paragraph IV consideration. What drug does US Patent 7,741,358 protect?The chemical compound in the claims is asenapine maleate, identified in the patent by its systematic name:
Asenapine is an atypical antipsychotic. The maleate salt is administered primarily through sublingual or buccal dosage forms. The FDA approved Saphris for acute treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. The approved indications were later expanded to include certain pediatric patients.[1] US Patent 7,741,358 is therefore a solid-state patent covering a commercially relevant form of the active ingredient rather than the original discovery patent for the asenapine molecule. What is the protected crystalline form?The claimed form is the orthorhombic polymorph of asenapine maleate. A polymorph has the same chemical composition as another crystal form but a different molecular arrangement in the solid state. Differences between polymorphs can affect:
Claim 1 sets a composition threshold of at least about 90 wt.% orthorhombic crystalline form. That threshold is important because it excludes material containing only a minor amount of the orthorhombic form. How many independent claims does US Patent 7,741,358 have?The patent has one independent product claim, one independent preparation claim, one independent composition claim and one independent treatment-method claim.
Claims 2 through 5 are dependent product claims. Claims 9 through 11 are dependent treatment claims. What is the scope of claim 1?Claim 1 is the broadest and most commercially important claim. It covers:
The claim does not require a particular particle size, tablet strength, excipient, packaging configuration, manufacturing scale or therapeutic indication. The claim also does not expressly require the XRPD or Raman peak sets recited in claims 2 through 5. Those analytical characteristics are evidence of the claimed crystal form, but claim 1 is drafted around the form and purity threshold rather than around a complete analytical fingerprint. What does the 90 wt.% threshold mean?The phrase "at least about 90 wt.%" creates a quantitative boundary. Material containing 90 wt.% or more of the orthorhombic form falls within the literal scope if the other claim elements are satisfied. Material containing less than 90 wt.% may avoid literal infringement of claim 1, but it could raise several technical and legal issues:
A generic applicant would need a reliable solid-state characterization package, not merely a nominal assertion that it uses a different form. What do claims 2 and 3 protect?Claims 2 and 3 define the orthorhombic form by X-ray powder diffraction using CuKα radiation. Claim 2 lists peaks at:
Claim 3 includes those peaks plus:
The 2-theta peak pattern is a crystallographic fingerprint. Claim 3 is narrower than claim 2 because it recites a larger set of peaks. The practical distinction is evidentiary:
Neither claim states a full relative-intensity profile, peak-width range or explicit angular tolerance in the user-provided claim text. Those details may affect infringement analysis and claim construction. What do claims 4 and 5 protect?Claims 4 and 5 use Raman spectroscopy rather than XRPD. Claim 4 recites peaks at:
Claim 5 adds:
Raman spectroscopy can distinguish polymorphs through vibrational modes associated with molecular packing and crystal symmetry. These claims provide alternative analytical routes for proving that a sample is the claimed orthorhombic form. A manufacturer could face infringement evidence based on either XRPD or Raman data. Avoiding a particular XRPD pattern would not necessarily avoid claims 4 or 5 if the material exhibits the claimed Raman pattern. What does claim 6 protect?Claim 6 covers a method of preparing the orthorhombic asenapine maleate form by crystallizing the compound from an ethanol/water mixture. The process claim requires:
The claim is narrower than claim 1 because a product can fall within claim 1 regardless of the process used. A manufacturer that produces the same orthorhombic form through another solvent system may avoid literal infringement of claim 6 while remaining exposed under claim 1. The process claim is most relevant to manufacturing records, batch instructions, solvent composition, seeding procedures, cooling profiles and solvent-removal conditions. What do claims 7 through 11 protect?What does claim 7 cover?Claim 7 covers a pharmaceutical composition containing:
The claim is directed to a finished pharmaceutical composition, not merely bulk drug substance. It can reach tablets or other dosage forms containing the protected polymorph, provided the composition satisfies the claim language. The phrase "prepared by using" creates an important product-by-process issue. In US patent law, product-by-process limitations generally do not permit a patentee to capture every identical product regardless of how it was made. Courts typically examine whether the claimed product itself has the required characteristics and whether the process limitation carries legal significance under the applicable claim construction. The precise effect depends on the prosecution history and judicial interpretation.[2] What do claims 8 through 11 cover?Claims 8 through 11 cover treatment of schizophrenia or bipolar disorder using the composition of claim 7. These claims are method-of-use claims rather than composition claims. They require:
Claim 9 narrows the patient to a human. Claim 10 narrows the disorder to schizophrenia. Claim 11 narrows it to bipolar disorder. The treatment claims have limited value against an ANDA applicant that seeks approval for the same indication but files a valid Paragraph IV certification or a section viii statement, depending on the listed use. Their practical enforcement value is stronger against commercial manufacture, marketing or prescribing conduct that directly practices the claimed method. When does US Patent 7,741,358 expire?The patent issued on June 22, 2010. Its 20-year US patent term is calculated from the applicable nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any patent-term extension. The patent's ordinary term is associated with an April 20, 2027 expiration date based on its US filing history. The exact effective date for enforcement requires review of the USPTO term calculation and any patent-term adjustment shown in the official record.[3]
The patent is distinct from the earlier compound patent covering asenapine itself. A compound patent can expire before a later polymorph patent, leaving the later patent as a solid-state barrier to products using the protected form. What is the Orange Book status of US Patent 7,741,358?US Patent 7,741,358 has been associated with Saphris, the FDA-approved asenapine maleate product. The relevant listing category is a drug-substance or active-ingredient patent directed to the orthorhombic form of asenapine maleate, rather than a conventional tablet-coating or packaging patent. The Orange Book significance is substantial because an ANDA applicant seeking approval for an asenapine product must address listed patents through:
The polymorph patent can therefore affect the timing of ANDA approval even after earlier patents covering the asenapine molecule have expired. Which companies have challenged asenapine patents?Generic activity for asenapine has involved ANDA applicants seeking approval for generic sublingual tablets. The relevant competitive group includes major generic companies and specialized US applicants that have filed or commercialized asenapine products. The principal legal question is not whether a generic applicant can make asenapine. It is whether the applicant can:
A complete company-by-company litigation conclusion requires the relevant district-court docket and settlement documents. The patent number alone does not establish whether a particular applicant filed a Paragraph IV certification, settled, launched at risk or entered under a license. What generic entry risks exist?Product-form riskThe largest risk is that the proposed generic contains at least about 90 wt.% of the orthorhombic form. If confirmed by XRPD, Raman testing or equivalent solid-state evidence, the product may fall within claim 1 and one or more dependent claims. Process riskA generic using ethanol and water to crystallize asenapine maleate may face claim 6 exposure. This risk depends on the exact process, including whether ethanol and water are used as a mixed crystallization solvent or in separate process steps. Composition riskA finished sublingual tablet containing the protected orthorhombic form may implicate claim 7. Excipients, strength and tablet geometry do not necessarily avoid the claim. Method-of-use riskA label that includes schizophrenia or bipolar-disorder treatment may implicate claims 8 through 11. A generic applicant may attempt a section viii carve-out for a patented use, but the carve-out must be consistent with the proposed labeling and applicable FDA requirements. Is there biosimilar risk for asenapine?No. Asenapine is a chemically synthesized small molecule, not a biologic. The relevant competition is generic ANDA competition, not biosimilar competition under the Public Health Service Act. The main regulatory issues are pharmaceutical equivalence, bioequivalence, dosage-form performance and solid-state comparability. The FDA's generic pathway does not require a biosimilar-style reference-product analytical and clinical package. What formulation patents compete with US 7,741,358?US 7,741,358 is principally a polymorph patent. It does not comprehensively claim every delivery system used for asenapine. The patent should be separated from later or parallel rights covering:
The Secuado transdermal system, for example, is a distinct product technology. A patent covering the orthorhombic active ingredient and a patent covering a transdermal delivery system can create overlapping but separate barriers. A company must analyze both the active ingredient form and the delivery platform. How strong is the patent estate?The patent estate is strongest where a manufacturer uses the same commercial solid form. Claim 1 is a direct product claim and does not depend on proving the crystallization route. Claims 2 through 5 provide multiple analytical definitions that can support infringement testing. Its principal limitations are:
How does this patent compare with the original asenapine patent?The original asenapine patent protects the active pharmaceutical compound and therapeutic uses at a broader chemical level. US 7,741,358 protects a later-developed physical form of the maleate salt.
The later polymorph patent can extend practical market protection beyond the compound patent, but only for products that use the claimed form or otherwise satisfy the asserted claims. Key Takeaways
FAQsDoes US Patent 7,741,358 cover all asenapine maleate?No. It is limited to the orthorhombic crystalline form containing at least about 90 wt.% of that form. Other polymorphs, amorphous material or different salt forms are not automatically covered. Can a generic company avoid the patent by using a different solvent?Potentially for claim 6, but not necessarily for claim 1. A different solvent may avoid the ethanol/water process limitation while still producing the claimed orthorhombic product. Are XRPD peaks required to prove infringement?No. Claims 2 and 3 expressly require specified XRPD patterns. Claim 1 is directed to the orthorhombic form and purity threshold, which may be established through XRPD, Raman spectroscopy, solid-state NMR, thermal analysis or other competent evidence. Does the patent cover Saphris tablets specifically?It covers compositions containing the claimed orthorhombic asenapine maleate form under claim 7. It does not require the brand name, a particular tablet strength or a particular excipient system. Can an ANDA applicant launch before April 2027?Only through a legally effective route such as a successful patent challenge, a non-infringing product and valid regulatory certification, a license or settlement permitting earlier entry, or another applicable exclusivity pathway. References
More… ↓ |
Drugs Protected by US Patent 7,741,358
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-003 | Mar 12, 2015 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Abbvie | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-001 | Aug 13, 2009 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Abbvie | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-002 | Aug 13, 2009 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
